Recommendation: Speculative Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 23 Jul, 25 | BDMD | Speculative Buy | USD 2.17 | USD 2.28 | USD 2.41 | Same day | Closed |
10.60%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
Net Income Surge: Net income increased by 85.8%, from USUSD 2.4 million to USUSD 4.4 million, reflecting improved profitability
Revenue Growth: Total revenues rose by 13.8%, from USUSD 11.5 million to USUSD 13.1 million year-over-year
Geographical Concentration: Despite FDA approval, current operations remain heavily reliant on the China market, with limited demonstrated revenue impact from U.S. expansion as of H1 2024
Revenue Growth Rate: While positive, the 13.8% growth may be seen as modest compared to the 85.8% net income growth, possibly suggesting slower topline expansion relative to bottom-line improvement
Baird Medical faces significant execution risk in scaling its operations in the U.S. market, where competitive dynamics, regulatory hurdles, and limited initial market penetration could delay its growth trajectory
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 2.17 | 1.95 | 2.28 | 2.41 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Strong Financial Growth in First Half of 2024: Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a prominent Chinese developer of microwave ablation (MWA) medical devices, reported robust preliminary financial results for the six months ended June 30, 2024. Total revenues increased by 13.8% year-over-year to USUSD 13.1 million, up from USUSD 11.5 million in the first half of 2023. The company’s gross profit also grew significantly, rising 20.9% to USUSD 11.5 million compared to USUSD 9.5 million in the prior-year period, reflecting operational strength and favorable product economics.
Operational Efficiency and Profitability: Baird Medical demonstrated strong operating leverage during the period, with operating income climbing 70.0% year-over-year to USUSD 5.1 million, up from USUSD 3.0 million in the same period last year. Net income rose even more sharply, increasing by 85.8% to USUSD 4.4 million from USUSD 2.4 million. These metrics underscore the company’s focus on cost discipline and its ability to translate revenue growth into bottom-line profitability.
Expansion into U.S. Market and Strategic Developments: The company has made strategic strides in global expansion, marked by its recent receipt of U.S. FDA 510(k) clearance for its MWA technology. This milestone supports Baird Medical’s entry into the U.S. market, where it aims to offer a minimally invasive alternative to traditional thyroidectomy—a market comprising approximately 150,000 procedures annually. In a significant corporate development, Baird Medical also completed a business combination with ExcelFin Acquisition Corp. on October 1, 2024. The combined entity began trading on Nasdaq under the ticker symbols “BDMD” and “BDMDW” as of October 2, 2024.
Outlook and Strategic Vision: Founder and CEO Ms. Haimei Wu emphasized the company’s dual focus on sustaining core business momentum in China and scaling operations in the U.S. With a growing international footprint and an innovative product portfolio, Baird Medical is positioned to capitalize on the demand for non-invasive tumor treatment solutions. The management remains committed to continued innovation, efficient growth, and enhancing access to its technology to improve patient outcomes and reduce healthcare costs.
Considering recent key business, financial updates, current trading levels, and key business risks, a ‘Speculative Buy’ recommendation has been given on Baird Medical Investment Holdings Ltd (NASDAQ: BDMD) at the closing market price of USD 2.17, as on July 22, 2025.
Data Powered by EOD Historical Data (“EODHD”).
Sector: Industry:
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) |
|---|---|---|---|---|---|---|
| BDMD Baird Medical Investment Holdings Limited |
0.04 1.96% | 2.08 | - | - | - | - |
Data Powered by EOD Historical Data (“EODHD”).
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is Jul 22,2025. The reference data in this report has been partly sourced from REFINITIV.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2023 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
